nach oben

Erschienen in:

01.03.2023 | Review Article

The past, present, and future of immunotherapy for colorectal cancer

verfasst von: Cole R. Formslag, Lei Zhao, Aidan J. Heslin, Cade C. Lewis, Caleb W. Miller, Qian Bai, Mark R. Wakefield, Yujiang Fang

Erschienen in: Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is prevalent worldwide, with various factors influencing the survival rate of late-stage metastatic cases. Current standard treatments include surgical removal, adjuvant chemotherapy, and neoadjuvant chemotherapy. Novel immunotherapy research shows promising results for various cancer types, including colorectal cancer. Current immunotherapy options are limited to specific molecular subtypes of colorectal cancer, while the remaining are limited to standard protocol. This review article summarizes approved, developing, and potential sources for novel colorectal cancer immunotherapy treatment through active-specific, checkpoint inhibitor, cytokine, cytotoxic, and adoptive T-cell immunotherapy. Such a study would be beneficial to patients with colorectal cancer.

Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. https://doi.org/10.3322/caac.21601.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–76. https://doi.org/10.2147/CIA.S109285.CrossRefPubMedPubMedCentral

Johnson CM, Wei C, Ensor JE, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24(6):1207–22. https://doi.org/10.1007/s10552-013-0201-5.CrossRefPubMedPubMedCentral

Lotfollahzadeh S, Recio-Boiles A, Cagir B. Colon Cancer. [Updated 2022 Dec 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/

Marschner N, Arnold D, Engel E, et al. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer—Results from a prospective cohort study. Clin Epidemiol. 2015;7:295–303. https://doi.org/10.2147/CLEP.S73857.CrossRefPubMedPubMedCentral

Costas-Chavarri A, Nandakumar G, Temin S, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol. 2019;5:1–19. https://doi.org/10.1200/JGO.18.00214.CrossRefPubMed

Price TJ, Thavaneswaran S, Burge M, et al. Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Rev Anticancer Ther. 2016;16(5):557–71. https://doi.org/10.1586/14737140.2016.1170594.CrossRefPubMed

De’Angelis GL, Bottarelli L, Azzoni C, et al. Microsatellite instability in colorectal cancer. Acta Biomed. 2018;89(9):97–101. https://doi.org/10.23750/abm.v89i9-S.7960.CrossRefPubMed

10.

Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75. https://doi.org/10.1038/s41575-019-0126-x.CrossRefPubMedPubMedCentral

11.

Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs. 2011;71(8):1093–104. https://doi.org/10.2165/11594010-000000000-00000.CrossRefPubMed

12.

Smith KM, Desai J. Nivolumab for the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2018;18(7):611–8. https://doi.org/10.1080/14737140.2018.1480942.CrossRefPubMed

13.

Hodi FS, O'Day SJ, McDermott DF, et al. 2010 Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010 Sep 23;363(13):1290]. N Engl J Med. 363(8):711–23. https://doi.org/10.1056/NEJMoa1003466

14.

Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. https://doi.org/10.1056/NEJMoa1104621.CrossRefPubMed

15.

Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMoa1412082.CrossRefPubMed

16.

Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/NEJMoa1504627.CrossRefPubMedPubMedCentral

17.

Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMed

18.

Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021;27(17):4680–4. https://doi.org/10.1158/1078-0432.CCR-21-0557.CrossRefPubMedPubMedCentral

19.

Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). N Engl J Med. 1974;290(25):1413–20. https://doi.org/10.1056/NEJM197406202902506.CrossRefPubMed

20.

Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern cooperative oncology group study E5283. J Clin Oncol. 2000;18(1):148–57. https://doi.org/10.1200/JCO.2000.18.1.148.CrossRefPubMed

21.

Cao JX, Zhang XY, Liu JL, et al. Validity of combination active specific immunotherapy for colorectal cancer: a meta-analysis of 2993 patients. Cytotherapy. 2015;17(12):1746–62. https://doi.org/10.1016/j.jcyt.2015.08.009.CrossRefPubMed

22.

Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–66. https://doi.org/10.1056/NEJMoa051424.CrossRefPubMed

23.

Wensveen FM, Jelenčić V, Polić B. NKG2D: a master regulator of immune cell responsiveness. Front Immunol. 2018;9:441. https://doi.org/10.3389/fimmu.2018.00441.CrossRefPubMedPubMedCentral

24.

Ghadially H, Brown L, Lloyd C, et al. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer. 2017;116(9):1208–17. https://doi.org/10.1038/bjc.2017.79.CrossRefPubMedPubMedCentral

25.

Espinoza I, Agarwal S, Sakiyama M, et al. Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer. Front Biosci (Landmark Ed). 2021;26(10):765–76. https://doi.org/10.52586/4986.CrossRefPubMed

26.

Courau T, Bonnereau J, Chicoteau J, et al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer. 2019;7(1):74. https://doi.org/10.1186/s40425-019-0553-9.CrossRefPubMedPubMedCentral

27.

Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(Suppl 3):S233-42. https://doi.org/10.1186/ar565.CrossRefPubMedPubMedCentral

28.

Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer—more than a “gut” feeling? Cell Div. 2010;5:14. https://doi.org/10.1186/1747-1028-5-14.CrossRefPubMedPubMedCentral

29.

Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993;260(5115):1808–10. https://doi.org/10.1126/science.8511589.CrossRefPubMed

30.

Xu J, Ye Y, Zhang H, et al. Diagnostic and prognostic value of Serum interleukin-6 in colorectal cancer. Medicine (Baltimore). 2016;95(2):e2502. https://doi.org/10.1097/MD.0000000000002502.CrossRefPubMed

31.

Han J, Meng Q, Xi Q, Zhang Y, Zhuang Q, Han Y, Jiang Y, Ding Q, Wu G. Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer. Int J Oncol. 2016;48(1):215–24. https://doi.org/10.3892/ijo.2015.3225.CrossRefPubMed

32.

Kitamura H, Ohno Y, Toyoshima Y, et al. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 2017;108(10):1947–52. https://doi.org/10.1111/cas.13332.CrossRefPubMedPubMedCentral

33.

Kitamura H, Kamon H, Sawa S, et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity. 2005;23(5):491–502. https://doi.org/10.1016/j.immuni.2005.09.010.CrossRefPubMed

34.

Li J, Xu J, Yan X, Jin K, Li W, Zhang R. Targeting interleukin-6 (IL-6) sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model. Med Sci Monit. 2018;24:5501–8. https://doi.org/10.12659/MSM.907439.CrossRefPubMedPubMedCentral

35.

Nishina T, Deguchi Y, Ohshima D, Takeda W, Ohtsuka M, Shichino S, Ueha S, Yamazaki S, Kawauchi M, Nakamura E, Nishiyama C, Kojima Y, Adachi-Akahane S, Hasegawa M, Nakayama M, Oshima M, Yagita H, Shibuya K, Mikami T, Inohara N, Matsushima K, Tada N, Nakano H. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat Commun. 2021;12(1):2281. https://doi.org/10.1038/s41467-021-22450-3.CrossRefPubMedPubMedCentral

36.

Huynh J, Baloyan D, Chisanga D, Shi W, O’Brien M, Afshar-Sterle S, Alorro M, Pang L, Williams DS, Parslow AC, Thilakasiri P, Eissmann MF, Boon L, Masson F, Chand AL, Ernst M. Host IL11 signaling suppresses CD4+ T cell-mediated antitumor responses to colon cancer in mice. Cancer Immunol Res. 2021;9(7):735–47. https://doi.org/10.1158/2326-6066.CrossRefPubMed

37.

Razi S, Baradaran Noveiry B, Keshavarz-Fathi M, Rezaei N. IL-17 and colorectal cancer: from carcinogenesis to treatment. Cytokine. 2019;116:7–12. https://doi.org/10.1016/j.cyto.2018.12.021.CrossRefPubMed

38.

Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407(2):348–54. https://doi.org/10.1016/j.bbrc.2011.03.021.CrossRefPubMed

39.

Chin CC, Chen CN, Kuo HC, Shi CS, Hsieh MC, Kuo YH, Tung SY, Lee KF, Huang WS. Interleukin-17 induces CC chemokine receptor 6 expression and cell migration in colorectal cancer cells. J Cell Physiol. 2015;230(7):1430–7. https://doi.org/10.1002/jcp.24796.CrossRefPubMed

40.

Lin Y, Xu J, Su H, et al. Interleukin-17 is a favorable prognostic marker for colorectal cancer. Clin Transl Oncol. 2015;17(1):50–6. https://doi.org/10.1007/s12094-014-1197-3.CrossRefPubMed

41.

Wang K, Karin M. The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S87-90.PubMed

42.

Blauvelt A. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. Expert Opin Biol Ther. 2016;16(2):255–63. https://doi.org/10.1517/14712598.2016.1132695.CrossRefPubMed

43.

Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, Han S, Zhan F, Luo S, Yao Y, Zheng T, Zhang Y. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9(1):e001895. https://doi.org/10.1136/jitc-2020-001895.CrossRefPubMedPubMedCentral

44.

Hu WH, Chen HH, Yen SL, Huang HY, Hsiao CC, Chuang JH. Increased expression of interleukin-23 associated with progression of colorectal cancer. J Surg Oncol. 2017;115(2):208–12. https://doi.org/10.1002/jso.24505.CrossRefPubMed

45.

Lee HH, Yang SS, Vo MT, et al. Tristetraprolin down-regulates IL-23 expression in colon cancer cells. Mol Cells. 2013;36(6):571–6. https://doi.org/10.1007/s10059-013-0268-6.CrossRefPubMedPubMedCentral

46.

Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676–89. https://doi.org/10.1038/nri.2016.95.CrossRefPubMed

47.

Chen X, Lu K, Timko NJ, Weir DM, Zhu Z, Qin C, Mann JD, Bai Q, Xiao H, Nicholl MB, Wakefield MR, Fang Y. IL-33 notably inhibits the growth of colon cancer cells. Oncol Lett. 2018;16(1):769–74. https://doi.org/10.3892/ol.2018.8728.CrossRefPubMedPubMedCentral

48.

Juat DJ, Hachey SJ, Billimek J, Del Rosario MP, Nelson EL, Hughes CCW, Zell JA. Adoptive T-cell therapy in advanced colorectal cancer: a systematic review. Oncologist. 2022;27(3):210–9. https://doi.org/10.1093/oncolo/oyab038.CrossRefPubMedPubMedCentral

49.

Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5–18. https://doi.org/10.2174/1389201019666180418095526.CrossRefPubMed

50.

Zhang C, Wang Z, Yang Z, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–58. https://doi.org/10.1016/j.ymthe.2017.03.010.CrossRefPubMedPubMedCentral

51.

Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–6. https://doi.org/10.1038/mt.2010.272.CrossRefPubMed

Titel: The past, present, and future of immunotherapy for colorectal cancer
verfasst von: Cole R. Formslag
Lei Zhao
Aidan J. Heslin
Cade C. Lewis
Caleb W. Miller
Qian Bai
Mark R. Wakefield
Yujiang Fang
Publikationsdatum: 01.03.2023
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-01967-1

Photodynamic therapy in oral cancer: a review of clinical studies

Review Article

Function of TRPC1 in modulating hepatocellular carcinoma progression

Original Paper

Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma

Original Paper

MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration

Original Paper

NLRP3 inflammasome activation By 17β-estradiol is a potential therapeutic target in hepatocellular carcinoma treatment

Open Access
Original Paper

Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC

Original Paper

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

20.04.2025
Melanom
Nachrichten

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

17.04.2025
Koloskopie
Nachrichten

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The past, present, and future of immunotherapy for colorectal cancer

Abstract

Weitere Artikel der Ausgabe 3/2023

Photodynamic therapy in oral cancer: a review of clinical studies

Function of TRPC1 in modulating hepatocellular carcinoma progression

Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma

MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration

NLRP3 inflammasome activation By 17β-estradiol is a potential therapeutic target in hepatocellular carcinoma treatment

Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten